News Report says MSD is in talks to buy Revolution Meds MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.
News Nine more companies sign pricing deals with Trump Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.
News MSD claims two national priority vouchers; report The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
News Padcev/Keytruda scores again in early bladder cancer Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.
News Are RSV shots next in line for restrictions in the US? After pushing for restrictions on vaccines for COVID-19 and hepatitis B, the Trump administration seems to be turning its attention to RSV shots.
News Setback for MSD as German court blocks Keytruda SC launch A court in Germany has granted an injunction that will prevent MSD from distributing the new, subcutaneous version of its cancer drug Keytruda.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.